We investigated the neuroprotective effects of the dopamine (DA) receptor agonist R-apomorphine (R-APO) (10mg/kg/day, s.c. for 11 days) in the striatal 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease (PD). The treatment was started either 15' before or 24h after lesioning. R-APO was also administered to intact rats. Two weeks after lesioning, the neuroprotective effects were evaluated using behavioural, neurochemical and histological tests. We also studied the effect of R-APO on the neurotrophic factor fibroblast growth factor 2 (FGF-2) mRNA expression in the striatum of intact rats. Both in the striatum and the substantia nigra pars compacta (SNpc), 6-OHDA induced a lesion of about 50%. The treatment significantly reduced the amphetamine-induced ipsiversive rotations, the size of the lesion at the level of the SNpc and ventral tegmental area (VTA), and the 6-OHDA induced striatal DA depletion. The number of cells in the VTA significantly increased in intact rats, suggesting a neurotrophic action of R-APO. Preliminary data show an increase of the striatal FGF-2 mRNA levels. We conclude that R-APO has a neuroprotective and possible neurotrophic effect in our rat model. This may, at least in part, be mediated by an up-regulation of FGF-2.
|Title of host publication||Belgian Society of Fundamental and Clinical Physiology and Pharmacology, Autumn meeting, 24th October 2009|
|Publication status||Published - 2009|
|Name||Belgian Society of Fundamental and Clinical Physiology and Pharmacology, Autumn meeting, 24th October 2009|
- Parkinson's disease
- 6-OHDA rat model